StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Evofem Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -15.3%. For fiscal 2025 it was 16.7%, against -39.6% the year before. The highest annual figure on record is 16.7% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202516.7%+56.3
FY2024Dec 31, 2024-39.6%+58.3
FY2023Dec 31, 2023-98.0%+401.7
FY2022Dec 31, 2022-499.6%+1523.7
FY2021Dec 31, 2021-2023.3%+21210.8
FY2020Dec 31, 2020-23234.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-94.5%−68.6
Q1 FY2026Mar 31, 2026-508.2%−546.9
Q4 FY2025Dec 31, 202535.0%+49.1
Q3 FY2025Sep 30, 202519.2%+73.5
Q2 FY2025Jun 30, 2025-25.9%+7.5
Q1 FY2025Mar 31, 202538.7%+117.6
Q4 FY2024Dec 31, 2024-14.1%+284.3
Q3 FY2024Sep 30, 2024-54.3%+7.3
Q2 FY2024Jun 30, 2024-33.4%+6625.2
Q1 FY2024Mar 31, 2024-78.9%+215.0
Q2 FY2023Jun 30, 2023-298.5%+106.2
Q1 FY2023Mar 31, 2023-61.6%+618.9
Q4 FY2022Dec 31, 2022-6658.6%−5610.4
Q3 FY2022Sep 30, 2022-293.9%+2239.3
Q2 FY2022Jun 30, 2022-404.7%+1810.8
Q1 FY2022Mar 31, 2022-680.5%+3380.3
Q4 FY2021Dec 31, 2021-1048.1%+20291.8
Q3 FY2021Sep 30, 2021-2533.2%+6875.4
Q2 FY2021Jun 30, 2021-2215.5%–
Q1 FY2021Mar 31, 2021-4060.8%–
Q4 FY2020Dec 31, 2020-21339.9%–
Q3 FY2020Sep 30, 2020-9408.6%–

More Evofem Biosciences figures

See a number that looks wrong?